NECFA
RUBY

New England Capital Financial Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

New England Capital Financial Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,107
Closed -$251 – 448
2022
Q4 		$251 Buy
+1,107
New +$302 ﹤0.01% 414

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

New England Capital Financial Advisors's RUBY Position: Q1 2023 in Review

New England Capital Financial Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 1,107 shares — an estimated $251 sold.

New England Capital Financial Advisors first reported a position in RUBY in Q4 2022 and held it in 1 quarter. The position peaked at $251 in Q4 2022. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • New England Capital Financial Advisors reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 1,107 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $251.
  • New England Capital Financial Advisors first reported a position in Rubius Therapeutics, Inc in Q4 2022 and held it in 1 quarter.
  • New England Capital Financial Advisors's Rubius Therapeutics, Inc position peaked at $251 in Q4 2022.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on New England Capital Financial Advisors's 13F filing for Q1 2023, filed 4 May 2023.